Axsome Therapeutics (NASDAQ: AXSM) reported Q3 EPS of ($0.95), $0.10 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $171 million versus the consensus estimate of $162.45 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.